 |
|
VIGNETTES
Neutrophilic Dermatosis (Sweet Syndrome) of the Hands Associated With Lenalidomide
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Lenalidomide (Revlimid; Celgene Corporation, Summit, NJ) is an amino-substituted variant of thalidomide that belongs to a class of analogues known as immunomodulatory drugs.1 Preliminary data show that this drug is effective in treating newly diagnosed and relapsed multiple myeloma, as well as transfusion-dependent, low-risk myelodysplastic syndromes.2-3 We report a case of neutrophilic dermatosis of the hands in a patient receiving lenalidomide therapy.
Report of a Case
A 67-year-old man presented with an 8-day history of a sudden onset of painful bullae involving the dorsa of the hands and fingers. The lesions began as tender, red papules and progressed to painful vesicles and bullae. Approximately 6 days before the onset of these lesions, the patient had been enrolled in a study protocol of single-agent lenalidomide for the treatment of agnogenic myeloid metaplasia.
On examination, the patient was febrile with a maximal temperature of 38.5°C. Examination of the skin indicated tender papules, plaques, and bullae measuring . . . [Full Text of this Article]
Comment
AUTHOR INFORMATION
Alyssa R. Hoverson, MD;
Mark D. P. Davis, MD;
Roger H. Weenig, MD;
Alexandra P. Wolanskyj, MD
|
